Travere Therapeutics Announces Proposed Public Offering of Common Stock
November 07, 2024 16:01 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and...
Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024
October 14, 2024 16:30 ET
|
Travere Therapeutics, Inc.
Travere Therapeutics will present 11 abstracts, including one late-breaking abstract, at the upcoming ASN Kidney Week 2024 in San Diego.
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
September 05, 2024 17:34 ET
|
Travere Therapeutics, Inc.
Travere Therapeutics announced that the U.S. FDA has granted full approval to FILSPARI® (sparsentan) to treat IgA nephropathy.
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
January 25, 2024 16:05 ET
|
Travere Therapeutics, Inc.
Travere Therapeutics has entered into an exclusive licensing agreement with Renalys Pharma to bring sparsentan to patients in Japan.
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
October 13, 2023 16:30 ET
|
Travere Therapeutics, Inc.
Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI® (sparsentan) in IgAN and Phase 3 DUPLEX Study of sparsentan in FSGS 11 total abstracts accepted for...
Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control, Irbesartan
September 21, 2023 07:30 ET
|
Travere Therapeutics, Inc.
FILSPARI® (sparsentan) achieved a clinically meaningful difference vs. irbesartan in eGFR total slope (1.0 mL/min/1.73m2 per year) [p= 0.058] and eGFR chronic slope (1.1 mL/min/1.73m2 per year)...
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
April 01, 2023 04:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, April 01, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced publication in The Lancet of the interim analysis of efficacy and safety data from the ongoing...
Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease
November 15, 2022 08:00 ET
|
Travere Therapeutics, Inc.
Developed in collaboration with the rare kidney disease community, RKD & Me aims to amplify the experiences of people living with rare kidney disease. SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE)...
Travere Therapeutics Reports Third Quarter 2022 Financial Results
October 27, 2022 16:01 ET
|
Travere Therapeutics, Inc.
EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second half of 2023 New PDUFA target action date for...
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022
October 26, 2022 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present data from its sparsentan programs,...